(CLN) Clariant - SW

Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: SW (Switzerland) | Market Cap: 2.542m CHF | Total Return: -3.2% in 12m

Specialty Chemicals, Catalysts, Adsorbents, Additives
Total Rating 30
Safety 79
Buy Signal -1.14
Specialty Chemicals
Industry Rotation: +3.5
Market Cap: 3.18B
Avg Turnover: 8.25M
Risk 3d forecast
Volatility28.8%
VaR 5th Pctl4.89%
VaR vs Median3.15%
Reward TTM
Sharpe Ratio-0.14
Rel. Str. IBD39.4
Rel. Str. Peer Group29.5
Character TTM
Beta0.598
Beta Downside0.692
Hurst Exponent0.479
Drawdowns 3y
Max DD53.09%
CAGR/Max DD-0.22
CAGR/Mean DD-0.42
EPS (Earnings per Share) EPS (Earnings per Share) of CLN over the last years for every Quarter: "2021-06": 0.21, "2021-09": 0.3, "2021-12": 0.4511, "2022-03": 0.2026, "2022-06": 0.28, "2022-09": 0.34, "2022-12": 0.3556, "2023-03": 0.28, "2023-06": 0.28, "2023-09": 0.2298, "2023-12": 0.2412, "2024-03": 0, "2024-06": 0.4753, "2024-09": 0, "2024-12": 0.26, "2025-03": 0, "2025-06": 0.3496, "2025-09": 0, "2025-12": -0.3091,
EPS CAGR: -50.81%
EPS Trend: -69.5%
Last SUE: -4.00
Qual. Beats: -1
Revenue Revenue of CLN over the last years for every Quarter: 2021-06: 2034, 2021-09: null, 2021-12: 2338, 2022-03: null, 2022-06: 2563, 2022-09: null, 2022-12: 2635, 2023-03: null, 2023-06: 2284, 2023-09: null, 2023-12: 2093, 2024-03: null, 2024-06: 2070, 2024-09: null, 2024-12: 2082, 2025-03: null, 2025-06: 1981, 2025-09: null, 2025-12: 1934,
Rev. CAGR: -7.52%
Rev. Trend: -91.4%
Last SUE: -0.04
Qual. Beats: 0

Warnings

Interest Coverage Ratio 0.9 is critical

Fakeout Choppy

Tailwinds

No distinct edge detected

Description: CLN Clariant

Clariant AG is a Swiss-based specialty chemicals manufacturer operating globally across three primary segments: Care Chemicals, Catalysts, and Adsorbents & Additives. The company supplies essential chemical components to diverse industries including agriculture, automotive, aviation, and home care. Founded in 1886, Clariant maintains a significant presence in mature European markets while expanding its distribution infrastructure across the Asia Pacific and the Americas.

The specialty chemicals sector is characterized by high barriers to entry due to intensive research and development requirements and complex patent landscapes. Unlike commodity chemical producers, specialty firms like Clariant focus on value-added functional effects, allowing for more resilient pricing power during fluctuations in raw material costs. The companys business model relies on integrating chemical engineering with specific industrial applications, such as syngas production and crop protection solutions.

Investors can further evaluate the companys valuation metrics and historical performance by reviewing the data on ValueRay. Clariant continues to support global supply chains through its portfolio of catalysts and additives designed for high-performance industrial electronics and construction materials.

Headlines to Watch Out For
  • Care Chemicals margins expand on high-value personal care and crop solutions
  • Catalyst segment revenue fluctuates with global petrochemical and refinery capital expenditure
  • Adsorbents and Additives demand tracks automotive and electronics production cycles
  • Raw material cost volatility and energy prices impact specialty chemical profitability
Piotroski VR-10 (Strict) 4.5
Net Income: -75.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.00 > 1.0
NWC/Revenue: 22.17% < 20% (prev 16.31%; Δ 5.87% < -1%)
CFO/TA 0.06 > 3% & CFO 379.0m > Net Income -75.0m
Net Debt (1.79b) to EBITDA (558.0m): 3.21 < 3
Current Ratio: 1.64 > 1.5 & < 3
Outstanding Shares: last quarter (326.8m) vs 12m ago -1.08% < -2%
Gross Margin: 31.19% > 18% (prev 31.05%; Δ 0.14% > 0.5%)
Asset Turnover: 64.52% > 50% (prev 66.28%; Δ -1.76% > 0%)
Interest Coverage Ratio: 0.92 > 6 (EBIT TTM 306.0m / Interest Expense TTM 334.0m)
Altman Z'' 3.50
A: 0.15 (Total Current Assets 2.23b - Total Current Liabilities 1.36b) / Total Assets 5.87b
B: 0.49 (Retained Earnings 2.91b / Total Assets 5.87b)
C: 0.05 (EBIT TTM 306.0m / Avg Total Assets 6.07b)
D: 0.55 (Book Value of Equity 2.02b / Total Liabilities 3.69b)
Altman-Z'' = 3.50 = A
Beneish M -3.27
DSRI: 0.82 (Receivables 691.0m/891.0m, Revenue 3.92b/4.15b)
GMI: 1.00 (GM 31.05% / 31.19%)
AQI: 0.93 (AQ_t 0.36 / AQ_t-1 0.39)
SGI: 0.94 (Revenue 3.92b / 4.15b)
TATA: -0.08 (NI -75.0m - CFO 379.0m) / TA 5.87b)
Beneish M = -3.27 (Cap -4..+1) = AA
What is the price of CLN shares?

As of June 20, 2026, the stock is trading at CHF 7.59 with a total of 1,172,880 shares traded.
Over the past week, the price has changed by +2.94%, over one month by +3.66%, over three months by +9.45% and over the past year by -3.23%.

Is CLN a buy, sell or hold?

Clariant has no consensus analysts rating.

Clariant (CLN) - Fundamental Data Overview as of 19 June 2026
Market Cap USD = 3.18b (2.54b CHF * 1.2511 CHF.USD)
P/E Forward = 11.8624
P/S = 0.6494
P/B = 1.2341
P/EG = 0.9016
Revenue TTM = 3.92b CHF
EBIT TTM = 306.0m CHF
EBITDA TTM = 558.0m CHF
Long Term Debt = 1.53b CHF (from longTermDebt, last quarter)
Short Term Debt = 369.0m CHF (from shortTermDebt, last quarter)
Debt = 2.20b CHF (from shortLongTermDebtTotal, last quarter) + Leases 172.0m
Net Debt = 1.79b CHF (calculated: Debt 2.20b - CCE 411.0m)
Enterprise Value = 4.33b CHF (2.54b + Debt 2.20b - CCE 411.0m)
Interest Coverage Ratio = 0.92 (Ebit TTM 306.0m / Interest Expense TTM 334.0m)
EV/FCF = 18.52x (Enterprise Value 4.33b / FCF TTM 234.0m)
FCF Yield = 5.40% (FCF TTM 234.0m / Enterprise Value 4.33b)
FCF Margin = 5.98% (FCF TTM 234.0m / Revenue TTM 3.92b)
Net Margin = -1.92% (Net Income TTM -75.0m / Revenue TTM 3.92b)
Gross Margin = 31.19% ((Revenue TTM 3.92b - Cost of Revenue TTM 2.69b) / Revenue TTM)
Gross Margin QoQ = 30.25% (prev 32.10%)
Tobins Q-Ratio = 0.74 (Enterprise Value 4.33b / Total Assets 5.87b)
Interest Expense / Debt = 15.16% (Interest Expense 334.0m / Debt 2.20b)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = 229.5m (EBIT 306.0m * (1 - 25.00%))
Current Ratio = 1.64 (Total Current Assets 2.23b / Total Current Liabilities 1.36b)
Debt / Equity = 1.09 (Debt 2.20b / totalStockholderEquity, last quarter 2.02b)
Debt / EBITDA = 3.21 (Net Debt 1.79b / EBITDA 558.0m)
Debt / FCF = 7.66 (Net Debt 1.79b / FCF TTM 234.0m)
Total Stockholder Equity = 2.11b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.24% (Net Income -75.0m / Total Assets 5.87b)
RoE = -3.55% (Net Income TTM -75.0m / Total Stockholder Equity 2.11b)
RoCE = 8.40% (EBIT 306.0m / Capital Employed (Equity 2.11b + L.T.Debt 1.53b))
RoIC = 4.90% (NOPAT 229.5m / Invested Capital 4.68b)
WACC = 9.62% (E(2.54b)/V(4.75b) * Re(8.10%) + D(2.20b)/V(4.75b) * Rd(15.16%) * (1-Tc(0.25)))
Discount Rate = 8.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -15.91 | Cagr: -0.32%
[DCF] Terminal Value 73.98% ; FCFF base≈215.2m ; Y1≈246.7m ; Y5≈363.1m
[DCF] Fair Price = 8.13 (EV 4.46b - Net Debt 1.79b = Equity 2.67b / Shares 328.9m; r=9.62% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -69.52 | EPS CAGR: -50.81% | SUE: -4.0 | # QB: -1
Revenue Correlation: -91.40 | Revenue CAGR: -7.52% | SUE: -0.04 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.23 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.70 | Chg30d=-3.90% | Revisions=-62% | GrowthEPS=+1186.0% | GrowthRev=-2.7%
EPS next Year (2027-12-31): EPS=0.83 | Chg30d=-2.30% | Revisions=-25% | GrowthEPS=+19.1% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: -62%